In vivo, SIN therapy downregulated protein expression of Bcl-2 (Figure 4D) and PCNA (Figure 4C) significantly in the PG tissues of mice with TP-induced BPH, indicating that SIN treatment ameliorated BPH through the apoptotic pathway, which was consistent with in vitro data. Here, BCL2 is linked to benign prostatic hyperplasia.